Skip Navigation



European Heart Journal Advance Access published online on November 29, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl410
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/1/13    most recent
ehl410v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amisten, S.
Right arrow Articles by Erlinge, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amisten, S.
Right arrow Articles by Erlinge, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriersof the Thr-87 variant of the ATP receptor P2Y11

Stefan Amisten1, Olle Melander2, Anna-Karin Wihlborg1, Göran Berglund2 and David Erlinge1,*

1 Department of Cardiology, Lund University Hospital, SE-221 85 Lund, Sweden
2 Department of Clinical Sciences,Malmö, Lund University, Lund, Sweden

Received 10 June 2006; revised 24 September 2006; accepted 9 November 2006.

* Corresponding author. Tel: +46 46172597; fax: +46 46157857. E-mail address: david.erlinge{at}med.lu.se

Aims Extracellular ATP acting on the P2Y11 receptor regulates inflammatory cells. We hypothesized that polymorphisms in the receptor could influence the risk of acute myocardial infarction (AMI).

Methods and results In the Malmö diet and cancer AMI case–control study (n=3732) the P2Y11 gene Thr-87 polymorphism was present in 19.8% of the controls and 22.9% in AMI patients (OR 1.21; P=0.03). Stronger associations were found in patients with family history (FH) of AMI, 1.32; early-onset (EO) AMI, 1.43; or EO AMI combined with FH, 1.50; supporting a genetic mechanism. The Thr-87 homozygotes had an even greater risk of AMI, 1.94 (P=0.04); and 2.48 in the EO AMI subgroup, suggesting a genetic dosage effect. In the cardiovascular risk factor group (n=6055), 21.3% carried the Thr-87 allele. C-reactive protein was elevated in Thr-87 carriers: 1.6 mg/L vs. 1.3 mg/L (P=0.001). No difference was seen for blood pressure, lipids, body mass index, smoking, or diabetes mellitus.

Conclusion The common Ala-87-Thr polymorphism of the P2Y11 receptor is associated with AMI and increased levels of C-reactive protein. We hypothesize that an inflammatory mechanism might be involved. The P2Y11 receptor is a promising new drug target in the prevention of AMI.

Key Words: P2Y • Receptor • Myocardial infarction • Inflammation • Genetics • Human


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.